Market revenue in 2023 | USD 7,948.8 million |
Market revenue in 2030 | USD 14,764.0 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Development, Contract Manufacturing |
Key market players worldwide | Catalent Inc, Lonza Group Ltd, Recipharm, Siegfried Holding AG, Thermo Fisher Scientific Inc, Labcorp Drug Development, Jabil Inc, Syngene, IQVIA Holdings Inc, Almac Group, Ajinomoto Co Inc, Alcami, Vetter Pharma-Fertigung |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to healthcare contract development and manufacturing organization market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 82.23% in 2023. Horizon Databook has segmented the France healthcare contract development and manufacturing organization market based on contract development, contract manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
France is anticipated to exhibit lucrative growth owing to an increase in the number of clinical trials that require fully equipped medical infrastructure. Increasing regulatory focus on quality control for manufacturing operations in France is likely to boost the market. As of 2016, France was ranked third among the EU nations and sixth across the world in terms of economy, highlighting its market potential.
Furthermore, supportive government initiatives, such as the Choose France event, which showcases the country’s economic appeal and encourages foreign investments, are anticipated to boost the market.
There are several specialized pharmaceutical and biotechnology CDMOs in France, such as Recipharm, Viant Medical, CELL for CURE, Minakem, Siegfried, Aenova, Eurofins CDMO, and PX' Therapeutics, which is contributing to market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the France healthcare contract development and manufacturing organization market , including forecasts for subscribers. This country databook contains high-level insights into France healthcare contract development and manufacturing organization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account